Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2)
- 1 August 2004
- journal article
- clinical trial
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 28 (8-9) , 645-650
- https://doi.org/10.1016/s0399-8320(04)95042-7
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)Annals of Oncology, 2001
- An investigational new drug treatment program for patients with gemcitabineCancer, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Cancer of the pancreas: 50 years of surgeryCancer, 1987